Overview

A Study to Evaluate the Effectiveness and Safety of Slow Release Hydromorphone HCL for Treatment of Patients With Osteoarthritis

Status:
Completed

Trial end date:
2005-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to compare the analgesic (a drug that relieves pain) effectiveness and safety of OROS hydromorphone HCI (slow release) 8 mg and 16 mg to placebo (no drug) in patients with osteoarthritis (OA).

Phase:

Phase 3

Details

Lead Sponsor:

Alza Corporation, DE, USA

Treatments:

Hydromorphone